Dr. Schwartz is a 30-year veteran of the Pharmaceutical Industry most recently in the role of Executive Director, Strategic Transactions for Bristol-Myers Squibb Company where he has more than a dozen completed transactions to his credit. He speaks frequently on the Biotech-Big Pharma dynamics and evolving research and treatment paradigms in oncology and is perhaps best known for predicting FDA’s rejection of Dendreon’s Provenge vaccine in 2007 (San Francisco Chronicle, March 30, 2007). Provenge ultimately won FDA approval in April, 2010. Dr. Schwartz founded RHS Advisors, LLC, a life-sciences consulting firm, in July 2010.
Netherlands based non-professional stocktrader with a private portfolio; good at stockpicking; not good at options. I prefer companies with a good ROI, ROE, PEG-ratio, good and inspiring management, a durable competative advantage. BUY AND ACCUMULATE (B&A) is my approach. I'm in the market for the company's profit, not the stockprice in the first place.
SkyTides focuses on deep due diligence research of over-hyped stocks, outright stock frauds and public company individuals of questionable character. We use financial analytics, market research, expert opinions, accounting review, litigation review and other investigative methods, to make our case.
I have written 2 dutch books on value investing: "Aandelen selecteren als waardebelegger" and "Beleggen in bull- en bearmarkten". See bol.com (search for the titles). As a mathematician (Ph.D.) I am most interested in investment strategies with statistically favorable returns. In particular I invest in net-nets (20-30% average annual returns). I find companies with low Enterprise Value/Earnings before Tax and Interest (EV/EBIT) and strong balance sheets (20% average annual returns) also very interesting. Since such stocks are rare I invest globally. Send me a message with your email address to get example articles of my premium research on Seeking Alpha.
Currently Vice President of Business Development dedicated to the discovery and creation of shareholder value for Life Science companies.
--Extensive Scientific Research experience in Pharmaceutical and Medical Device Companies AMGEN, ALLERGAN
--Experience as Technical Liaison/Advisor for prominent financial institutions focused on Healthcare and Biotech investments
Prior experience includes:
AMGEN: (Research Scientist ) Drug Product Process Development, Drug Engineering, FDA technology- liaison, Product Characterization, Commercial Manufacturing Support, Commercial Drug Development , Drug Formulation and Pre-commercial Drug Product Tech Transfer.
ALLERGAN: (Research Scientist) Project design and management of proprietary materials and data for medical device and medical aesthetic products. Scientific research team lead of collagen and capsular-contracture studies for devices. Biomaterial optimization applying advanced histology, cell culture and immunohistochemistry.
OPUS Point Partners/OPN Capital Markets/ National Securities: Scientific Advisor and technology liaison. Worked alongside lead market strategist and lead biotech analyst at National Securities for The Biotech Group. Lead the due diligence process for the Managing Director at OPN Capital Markets, reviewing product mechanisms,intellectual property and overall technology/concept viability.